OLink is a high quality proteomics company, involved in the UK Biobank Pharma Proteomics Project, that resulted in an updated genetic atlas of the plasma proteome. With the recent establishment of the Oxford-GSK Institute, Olink® Explore will be utilized to build a multiomics approach to mapping molecular mechanisms of complex diseases such as Parkinson’s and Alzheimer’s. Expertise in machine learning and bioinformaticians at Oxford’s Big Data Institute will be able to leverage these datasets to pinpoint novel targets and identify signatures to stratify patients.